PDGFRβ(557-end), active, GST tagged human
SIGMA/G8671 - PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution
Synonym: CD140B; JTK12; PDGFR1
Product Type: Chemical
| assay | ≥70% (SDS-PAGE) |
| form | buffered aqueous glycerol solution |
| mol wt | ~104 kDa |
| product line | PRECISIO® Kinase |
| Quality Level | 200 ![]() |
| recombinant | expressed in baculovirus infected Sf9 cells |
| shipped in | dry ice |
| specific activity | 16-22 nmol/min·mg |
| storage temp. | −70°C |
| UniProt accession no. | P09619 ![]() |
| Biochem/physiol Actions: | PDGFRB (platelet derived growth factor receptor β), upon interaction with PGDFB, regulates multiple processes such as, sclerotic disorders, wound healing and tumor angiogenesis. Gain-of-function mutation in this gene is linked with Penttinen syndrome, which is an autosomal-dominant disorder. Release of PGDFB by endothelial cells results in the activation of this receptor, which is essential for the recruitment of PDGFRB+ vascular smooth muscle cells and pericytes during blood vessel formation. Loss-of-function mutation in this gene results in the neurodegenerative disorder primary familial brain calcification (PFBC). |
| General description: | PDGFRB (platelet derived growth factor receptor β) is a type III tyrosine kinase receptor, which exists as a homodimer. This receptor interacts with multiple ligands, but its main physiological ligand is PDGF-BB homodimer. |
| Legal Information: | PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Physical form: | Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.2 5mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥70% (SDS-PAGE) |
| activity | specific activity: 16-22 nmol/min·mg |
| Storage Temp. | −70°C |
| UNSPSC | 12352200 |

